Collectively, these findings underscore the therapeutic relevance of targeting HDAC1 and SIRT1 to restore tumor-suppressive miRNA expression and enhance chemosensitivity, providing a mechanistic basis for overcoming resistance in TNBC and other malignancies. Here, SIRT1 is linked to neoplasm.